Manabu Tashiro

Dr. Manabu Tashiro


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MTManabu Tashiro
Manabu Tashiro
KOKazuyoshi Okada
Kazuyoshi Okada
YTYusaku Tanaka
Yusaku Tanaka
HMHiroyuki Michiwaki
Hiroyuki Michiwaki
HSHisato Shima
Hisato Shima
JMJun Minakuchi
Jun Minakuchi
Background: Online hemodiafiltration (OHDF) has a lower mortality rate than hemodialysis (HD). We aimed to investigate the impact of the albumin leakage on the mortality of patients receiving HD or OHDF. Methods: In this single-center study, consecutive patients receiving renal replacement therapy between January and April 2018 were retrospectively registered. Using (1:1) propensity score matching, 3-year all-cause mortality was compared between patients receiving HD and OHDF, and the impact of albumin leakage on the mortality rate in both groups was investigated. Results: Of the 460 patients, 137 patients receiving HD were matched with an equal number of patients receiving OHDF. OHDF was associated with higher albumin leakage (p < 0.001) and a lower mortality than HD (log-rank test, p < 0.001). Albumin leakage was associated with mortality in patients receiving HD (per 1 g increase, hazard ratio (HR): 0.495, 95% confidence interval (CI): 0.275–0.888) and patients receiving OHDF (per 1 g increase, HR: 0.734, 95% CI: 0.588–0.915). Patients receiving HD, with the highest albumin leakage tertile (>3 g), had a similar mortality rate to patients receiving OHDF, with similar albumin leakage. Conclusions: The negative relationship between albumin leakage and mortality suggests the benefit of removing middle- to -large-molecular-weight substances to improve survival.

5 March 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
MTManabu Tashiro
Manabu Tashiro
SYSatoshi Yamada
Satoshi Yamada
MMMotokazu Matsuura
Motokazu Matsuura
KOKazuyoshi Okada
Kazuyoshi Okada
SKShu Kawashima
Shu Kawashima
Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as acute kidney injury. We report a biopsy-proven case of diffuse tubulointerstitial nephritis induced by cilostazol. A 69-year-old woman prescribed cilostazol was hospitalized for acute kidney injury. On admission, her renal function deteriorated, with an increased serum creatinine level. Urinalysis showed hematuria, proteinuria, and hyper-beta2-microglobulinuria. A renal biopsy revealed diffuse tubulointerstitial nephritis associated with IgA nephropathy, and gallium-67 scintigraphy showed uptake in the bilateral kidneys. A drug lymphocyte stimulation test for cilostazol was positive, and the patient was diagnosed with cilostazol-induced acute tubulointerstitial nephritis. Despite discontinuation of cilostazol, her renal function rapidly worsened and steroid pulse therapy was initiated, followed by oral high-dose glucocorticoid therapy. After steroid treatment, her serum creatinine level normalized in parallel with urine beta2-microglobulin. Cilostazol can induce acute tubulointerstitial nephritis.

10 April 2023 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
TDToshio Doi
Toshio Doi
TOTakuya Okamoto
Takuya Okamoto
TITomoko Inoue
Tomoko Inoue
MTManabu Tashiro
Manabu Tashiro
JMJun Minakuchi
Jun Minakuchi
Background: Crescentic immunoglobulin A (IgA) nephropathy, defined as > 50% of the glomeruli with crescents, often has a poor renal prognosis. Because of the high prevalence of pre-eclampsia in the second trimester of pregnancy, we often fail to investigate the new onset of glomerulonephritis and the aggravation of subclinical nephropathies. We report a case of nephrotic syndrome suggestive of crescentic IgA nephropathy possibly triggered by pregnancy. Case presentation: A 33-year-old multipara was referred for persistent proteinuria, hematuria, and hypoalbuminemia two months postpartum. The patient was diagnosed with proteinuria for the first time at 36 weeks of gestation. The patient was normotensive during pregnancy. Renal biopsy revealed crescentic IgA nephropathy, with cellular crescents in 80% of the glomeruli and no global sclerosis. After treatment with pulse steroids followed by high-dose oral glucocorticoids and tonsillectomy, a gradual improvement was seen in proteinuria, hematuria, and hypoalbuminemia. Conclusion: Although the precise mechanism remains unclear, pregnancy possibly triggered the new onset of crescentic IgA nephropathy or the aggravation of subclinical IgA nephropathy.

9 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KOKazuyoshi Okada
Kazuyoshi Okada
MTManabu Tashiro
Manabu Tashiro
HMHiroyuki Michiwaki
Hiroyuki Michiwaki
DHDaisuke Hara
Daisuke Hara
SAShimpei Araki
Shimpei Araki
JMJun Minakuchi
Jun Minakuchi
Controlled hypoalbuminemia due to high albumin leakage (Alb-L) improves mortality in dialysis patients with mild weight loss and/or inflammation. However, no study has investigated whether it reduces mortality in old-old patients who tend to have progressively worsening hypoalbuminemia, weight loss, and inflammation over time. To address this question, this study retrospectively analyzed 227 dialysis patients aged ≥75 years who were classified into a high Alb-L group (≥3 g/session, n = 93) and a low Alb-L group (<3 g/session, n = 134). Propensity score matching was performed to compare 3-year all-cause mortality, yielding 93 matched patients in each group. In our facilities, hypoalbuminemia due to high Alb-L was acceptable down to serum Alb (S-Alb) of 3.0 g/dL in patients without overt weight loss and/or inflammation. Survival was assessed using Kaplan–Meier survival curves with patients censored when their Alb-L category changed during annual follow-up assessments. Mortality was significantly lower in the high Alb-L group than in the low Alb-L group (P = 0.007, log-rank test). Adjusted Cox proportional hazards regression analysis showed that mortality remained significantly lower in the high Alb-L group (adjusted hazard ratio [HR] 0.397, 95% confidence interval 0.184-0.859, P = 0.019). In a sensitivity analysis using the overlap weighting method in all 227 patients without censoring for changes in Alb-L category, the HR for high Alb-L remained below 1.0, but was not statistically significant relative to low Alb-L. In exploratory hypothesis-generating stratified subgroup analyses, body mass index (BMI) ≥20 kg/m2, high-sensitivity C-reactive protein (hs-CRP) level ≥0.3 mg/dL, and a group with BMI <22 kg/m2 and/or hs-CRP level ≥0.3 mg/dL were associated with lower mortality rates in high Alb-L than in low Alb-L, while no associations were observed for BMI <20 kg/m2, hs-CRP level <0.3 mg/dL, and a group with BMI ≥22 kg/m2 and hs-CRP <0.3 mg/dL. Although low Alb-L was associated with reduced S-Alb and BMI, and elevated serum creatinine (S-Cr) after 3 years, high Alb-L were associated with increased BMI, decreased S-Cr, and the prevention of reduced S-Alb level. Furthermore, in patients without inflammation, either high or low Alb-L was associated with elevated hs-CRP level after 3 years. In contrast, controlled hypoalbuminemia due to high Alb-L was associated with decreased hs-CRP level in patients with mild inflammation, but low Alb-L was not. Controlled hypoalbuminemia due to high Alb-L was associated with lower mortality relative to low Alb-L in exploratory analyses of patients aged ≥75 years with mild weight loss and/or inflammation.